![[IPWatchdog Logo]](https://ipwatchdog.com/wp-content/themes/IPWatchdog%20-%202023/assets/images/temp/logo-small@2x.png){kind=logo}
Taskeen Aman
Associate
Venable LLP
Taskeen Aman is a law clerk in Venable LLP’s Intellectual Property Litigation Group.During Taskeen’s final year at the University of New Hampshire (UNH) Franklin Pierce School of Law, she served as a judicial intern for the Honorable Michael A. Shipp in the U.S. District Court for the District of New Jersey. Prior to law school, she gained years of wet-bench experience while pursuing her undergraduate degree in applied bioscience and her master’s degree in healthcare biotechnology from the National University of Sciences and Technology (NUST).
Recent Articles by Taskeen Aman
Patent Term Adjustment (PTA) was designed to serve an important purpose – to compensate patentees for time lost during examination due to U.S. Patent and Trademark Office (USPTO) delays. Most industries rely heavily on their patent portfolios to drive business strategies that ultimately impact their bottom line. The impact of patent term is especially acute in the pharmaceutical and biotechnology industries, where companies spend billions of dollars to develop new drugs. For these companies, every day that their patent is in force matters, generating millions in additional revenue. With so much at stake, companies strive to accrue all the patent term they are entitled to under the current statutory regime, including by way of PTA.
